Hologic/$HOLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Ticker

$HOLX
Sector
Primary listing

Employees

7,063

Hologic Metrics

BasicAdvanced
$15B
28.26
$2.41
0.49
-

What the Analysts think about Hologic

Analyst ratings (Buy, Hold, Sell) for Hologic stock.

Bulls say / Bears say

Private equity firms Blackstone and TPG have renewed talks to take Hologic private at a $14.7 billion valuation (around $66 per share), signaling confidence in the company’s operational comeback and the value of its women’s health products, with negotiations referencing mid-single-digit annual revenue growth for fiscal 2026 driven by new product launches and efforts to offset tariffs.
In fiscal 2025's first quarter, Hologic’s diagnostics division—the company’s largest by revenue—posted $470.6 million in sales, topping the $461 million consensus and showing steady demand for molecular diagnostics tests.
In the third quarter of fiscal 2025, Hologic reported strong liquidity, with $343.2 million in operating cash flow and $1.88 billion in cash plus short-term investments. This supports a low adjusted net leverage ratio of 0.6 times, giving the company flexibility for investing in growth and buying back shares.
Hologic cut its fiscal 2025 revenue forecast to $4.05 billion–$4.10 billion due to weak sales in breast health products and continued saline shortages, causing the stock to fall 5 percent after hours.
The company reduced its adjusted profit outlook for fiscal 2025 to $4.15–$4.25 per share, citing tariff uncertainties and geopolitical factors—projecting a $20–$25 million headwind each quarter—which pushed margins lower and caused shares to dip 3 percent.
Hologic’s stock has dropped about 24 percent year-to-date amid U.S. tariffs on China and Costa Rica and slower mammography equipment demand, highlighting ongoing challenges in its core breast health business.
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

Hologic Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Hologic Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HOLX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs